RecruitingPhase 3NCT07494409

A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia

A Phase 3, Multi-center, Randomized, Open-Label, Active-Controlled, Efficacy and Safety Study of AND017 to Treat Anemia in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia

Sponsor

Kind Pharmaceuticals LLC

Enrollment

300 participants

Start Date

Oct 31, 2025

Study Type

INTERVENTIONAL

Conditions

Anemia Due to Chronic Kidney Disease

Summary

This is a phase III, randomized, open-label, active-controlled study to evaluate the safety and efficacy of AND017 in anemic patients with End-Stage-Kidney-Disease (ESKD)

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AND017 capsules and a drug called ESA for people with anemia due to chronic kidney disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAND017 capsules

AND017 capsules administered orally with a starting dose of 10 mg TIW

DRUGESA

ESA injection and dose based on package insert and local practice

Locations(1)

Fudan Univeristy Zhongshan Hospital

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07494409

Related Trials

A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)

NCT074877271 location